New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under] > LEU - GMALL T-LBL 1/2004 VM26/ARAC
This regimen is a component of LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under]

GMALL T-LBL 1/2004 [55 years and under] - VM26/ARAC (LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under])

Treatment Overview

Commencing week 36.

Cycle 1 - 5 days

Cycle length:
5

Intrathecal metHOTREXATe: For Ommaya reservoir reduce dose to 6 mg intraventricularly.


teniposide: Hypersensitivity reactions can occur on first and subsequent administrations. Administer appropriate pre-medications if patient had a previous infusion related reaction of a grade where re-challenge is possible.

Cycle details

Cycle 1 - 5 days

Medication Dose Route Days Max Duration
metHOTREXATe 12 mg flat dosing intrathecal injection 1
cytarabine 30 mg flat dosing intrathecal injection 1
hydrocortisone * 30 mg flat dosing intrathecal injection 1
cytarabine 150 mg/m² Once daily intravenous 1 to 5 60 minutes
teniposide 100 mg/m² Once daily intravenous 1 to 5 60 minutes

Intrathecal metHOTREXATe: For Ommaya reservoir reduce dose to 6 mg intraventricularly.


teniposide: Hypersensitivity reactions can occur on first and subsequent administrations. Administer appropriate pre-medications if patient had a previous infusion related reaction of a grade where re-challenge is possible.

Full details

Cycle 1 - 5 days

Day: 1

Medication Dose Route Max duration Details
metHOTREXATe 12 mg flat dosing intrathecal injection
Instructions:
  • Adhere to local institution policy for intrathecal administration.
  • For Ommaya reservoir reduce dose to 6 mg intraventricularly.
cytarabine 30 mg flat dosing intrathecal injection
Instructions:

Adhere to local institution policy for intrathecal administration.
hydrocortisone * 30 mg flat dosing intrathecal injection
Instructions:

Adhere to local institution policy for intrathecal administration.
cytarabine 150 mg/m² Once daily intravenous 60 minutes
teniposide 100 mg/m² Once daily intravenous 60 minutes
Instructions:
  • Prepare solution in PVC-free bag and administer via polyethylene lined administration set.
  • Hypersensitivity reactions can occur on first and subsequent administrations.
  • Administer appropriate pre-medications if patient had a previous infusion related reaction of a grade where re-challenge is possible.

Day: 2

Medication Dose Route Max duration Details
cytarabine 150 mg/m² Once daily intravenous 60 minutes
teniposide 100 mg/m² Once daily intravenous 60 minutes
Instructions:
  • Prepare solution in PVC-free bag and administer via polyethylene lined administration set.
  • Hypersensitivity reactions can occur on first and subsequent administrations.
  • Administer appropriate pre-medications if patient had a previous infusion related reaction of a grade where re-challenge is possible.

Day: 3

Medication Dose Route Max duration Details
cytarabine 150 mg/m² Once daily intravenous 60 minutes
teniposide 100 mg/m² Once daily intravenous 60 minutes
Instructions:
  • Prepare solution in PVC-free bag and administer via polyethylene lined administration set.
  • Hypersensitivity reactions can occur on first and subsequent administrations.
  • Administer appropriate pre-medications if patient had a previous infusion related reaction of a grade where re-challenge is possible.

Day: 4

Medication Dose Route Max duration Details
cytarabine 150 mg/m² Once daily intravenous 60 minutes
teniposide 100 mg/m² Once daily intravenous 60 minutes
Instructions:
  • Prepare solution in PVC-free bag and administer via polyethylene lined administration set.
  • Hypersensitivity reactions can occur on first and subsequent administrations.
  • Administer appropriate pre-medications if patient had a previous infusion related reaction of a grade where re-challenge is possible.

Day: 5

Medication Dose Route Max duration Details
cytarabine 150 mg/m² Once daily intravenous 60 minutes
teniposide 100 mg/m² Once daily intravenous 60 minutes
Instructions:
  • Prepare solution in PVC-free bag and administer via polyethylene lined administration set.
  • Hypersensitivity reactions can occur on first and subsequent administrations.
  • Administer appropriate pre-medications if patient had a previous infusion related reaction of a grade where re-challenge is possible.

Supportive Care Factors

Factor Value
Antifungal prophylaxis: Routine antifungal prophylaxis recommended
Antiviral prophylaxis for herpes virus: Routine antiviral prophylaxis recommended
Emetogenicity: Low
Pneumocystis jirovecii pneumonia (PJP) prophylaxis: Routine antibiotic prophylaxis recommended

Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.

References

No references

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.